Novo Nordisk: Switch To Weekly Ozempic Has Begun, Biopharma M&A Sought
Executive Summary
But elephant in the room – the coming stream of readouts from Phase III PIONEER trials on oral semaglutide in Type 2 diabetes – gets little mention at first-quarter update.
You may also be interested in...
Novo's Oral Semaglutide Passes PIONEER 2, But Weight Loss Result A Bit Disappointing
In second Phase III diabetes study to report, oral GLP-1 agonist semaglutide misses some weight loss goals when compared with Boehringer/Lilly's SGLT-2 inhibitor Jardiance.
Novo Nordisk Boosts Specialty R&D With Kidney Disease Deal
Denmark's diabetes specialty company has linked up with a US biotech to evaluate a lysophosphatidic acid receptor antagonist in diabetic and chronic kidney disease.
Novo Nordisk's Oral Semaglutide Succeeds In First Phase III, But Prompts Questions
In PIONEER 1, weight loss results for the oral version of the GLP-1 agonist were somewhat disappointing and lack of detail in the top-line release prompts concerns about compliance.